Free Trial
→ Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry.' (From Brownstone Research) (Ad)

Exact Sciences Q4 2023 Earnings Report

Exact Sciences logo
$49.26 -0.25 (-0.50%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Exact Sciences EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.53
Beat/Miss
Beat by +$0.26
One Year Ago EPS
-$0.72

Exact Sciences Revenue Results

Actual Revenue
$646.89 million
Expected Revenue
$638.83 million
Beat/Miss
Beat by +$8.06 million
YoY Revenue Growth
+17.00%

Exact Sciences Announcement Details

Quarter
Q4 2023
Date
2/21/2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Slide Deck

Full Screen Slide Deck
Powered by Quartr

Exact Sciences Earnings Headlines

Exact Sciences price target lowered to $65 from $72 at BofA
February 21 at 8:19 PM | markets.businessinsider.com
Exact Sciences (EXAS) Receives a Buy from Piper Sandler
February 21 at 4:26 AM | markets.businessinsider.com
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
February 22, 2025 | WealthPress (Ad)
Why Exact Sciences (EXAS) Shares Are Trading Lower Today
February 20 at 10:17 PM | msn.com
Exact Sciences (EXAS) Receives a Buy from Citi
February 20 at 8:16 AM | markets.businessinsider.com
Exact Sciences price target lowered to $65 from $75 at BTIG
February 20 at 8:16 AM | markets.businessinsider.com
See More Exact Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exact Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exact Sciences and other key companies, straight to your email.

About Exact Sciences

Exact Sciences (NASDAQ:EXAS) provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

View Exact Sciences Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles